Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Turk J Haematol
Autori principali: Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman İ., Haznedaroğlu, İbrahim C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Galenos Publishing 2015
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451485/
https://ncbi.nlm.nih.gov/pubmed/26316485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2013.0265
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi